NasdaqGM:TRVIPharmaceuticals
Trevi Therapeutics (TRVI) Is Up 10.5% After Seeking Major Share Increase For Added Strategic Flexibility
In April 2026, Trevi Therapeutics filed proxy materials for its June 3, 2026 virtual annual meeting, asking shareholders to approve an Amended and Restated 2019 Stock Incentive Plan adding 8,000,000 shares and to double authorized common shares from 200,000,000 to 400,000,000, alongside routine director, auditor and compensation votes.
This large increase in potential equity capacity signals management’s interest in keeping financing, employee incentives and possible collaborations flexible...